JP2023519970A5 - - Google Patents
Info
- Publication number
- JP2023519970A5 JP2023519970A5 JP2022559564A JP2022559564A JP2023519970A5 JP 2023519970 A5 JP2023519970 A5 JP 2023519970A5 JP 2022559564 A JP2022559564 A JP 2022559564A JP 2022559564 A JP2022559564 A JP 2022559564A JP 2023519970 A5 JP2023519970 A5 JP 2023519970A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition according
- tnfα
- tnfα signaling
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003209P | 2020-03-31 | 2020-03-31 | |
| US63/003,209 | 2020-03-31 | ||
| PCT/US2021/025260 WO2021202801A1 (en) | 2020-03-31 | 2021-03-31 | Augmenting antigen-negative cell death in antigen-targeted immunotherapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519970A JP2023519970A (ja) | 2023-05-15 |
| JP2023519970A5 true JP2023519970A5 (https=) | 2024-03-19 |
Family
ID=77928465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559564A Pending JP2023519970A (ja) | 2020-03-31 | 2021-03-31 | 抗原ターゲティングされた免疫療法における抗原陰性細胞死の増進 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230218669A1 (https=) |
| EP (1) | EP4126016A4 (https=) |
| JP (1) | JP2023519970A (https=) |
| KR (1) | KR20220162133A (https=) |
| CN (1) | CN115361968A (https=) |
| WO (1) | WO2021202801A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022303363A1 (en) * | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023022235A1 (ja) * | 2021-08-20 | 2023-02-23 | 大塚製薬株式会社 | 組み合わせ医薬 |
| EP4673161A2 (en) * | 2023-03-02 | 2026-01-07 | Case Western Reserve University | Oncostatin-m-based chimeric antigen receptor (car)-immune cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7623784B2 (ja) * | 2016-10-13 | 2025-01-29 | ジュノー セラピューティクス インコーポレイテッド | トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物 |
| CA3048648A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| JP2021500859A (ja) * | 2017-09-22 | 2021-01-14 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | Ｎｆｋｂシグナル伝達の増強を伴うキメラ抗原受容体 |
| AU2019215031C1 (en) * | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| EP3814369A1 (en) * | 2018-06-29 | 2021-05-05 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Tweak-receptor agonists for use in combination with immunotherapy of a cancer |
| WO2020028572A2 (en) * | 2018-08-01 | 2020-02-06 | Unum Therapeutics Inc. | ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF |
-
2021
- 2021-03-31 JP JP2022559564A patent/JP2023519970A/ja active Pending
- 2021-03-31 CN CN202180024942.1A patent/CN115361968A/zh active Pending
- 2021-03-31 WO PCT/US2021/025260 patent/WO2021202801A1/en not_active Ceased
- 2021-03-31 EP EP21780314.7A patent/EP4126016A4/en active Pending
- 2021-03-31 KR KR1020227035400A patent/KR20220162133A/ko active Pending
- 2021-03-31 US US17/907,657 patent/US20230218669A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| Safarzadeh Kozani et al. | Nanobody-based CAR-T cells for cancer immunotherapy | |
| Klein et al. | The present and future of bispecific antibodies for cancer therapy | |
| Fabian et al. | The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy | |
| Chang et al. | Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells | |
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| Chen et al. | Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells | |
| Hoseini et al. | Acute myeloid leukemia targets for bispecific antibodies | |
| JP2021514631A5 (https=) | ||
| Zhao et al. | A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity | |
| Li et al. | The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling | |
| JP7590034B2 (ja) | Ｎｋｇ２ａを標的にする抗体及びその使用 | |
| Willemsen et al. | T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production | |
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells | |
| Hoseini et al. | Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies | |
| JP2023519970A5 (https=) | ||
| JP2024534471A5 (https=) | ||
| CN112638950B (zh) | 一种双特异性抗体 | |
| JP2015527070A5 (https=) | ||
| JP2021519072A5 (https=) | ||
| Utkarsh et al. | CAR-T cell therapy: a game-changer in cancer treatment and beyond | |
| CN114015656A (zh) | 用于同种异体移植的工程化免疫细胞 | |
| JP2024534417A5 (https=) | ||
| Maruta et al. | Direct comparison of target-reactivity and cross-reactivity induced by CAR-and BiTE-redirected T cells for the development of antibody-based T-cell therapy | |
| CN110423757B (zh) | 一种工程化核酸、t细胞及其应用和产生方法 |